for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Novartis Announces EU Approval Of MS Drug Mayzent For Certain Adult Patients

Jan 20 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) WITH ACTIVE DISEASE

* APPROVAL IS BASED ON PHASE III EXPAND TRIAL Source text for Eikon: Further company coverage: (Berlin Speed Desk)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up